Regulatory & PolicyJazz Pharmaceuticals recently sold one of its Priority Review Vouchers (PRVs) for $200 million, marking a substantial financial transaction as the future of the PRV program hangs in the balance due to legislative delays. The details of the buyer remain undisclosed, and the allocation of the remaining proceeds is unclear, emphasizing the nuanced complexities in biotech regulatory incentives.
TCB Team·Jan 15, 2026
Biotech InnovationIn the face of significant financial challenges impacting biomedical research, new data reveal a surprising uptick in graduate student enrollment in biomedical degree programs across the United States. This trend underscores the resilience and continued interest in the biomedical field, reflecting a potential shift in future research dynamics despite economic headwinds.
TCB Team·Jan 15, 2026 
Healthcare InvestmentThe healthcare sector is witnessing unprecedented private equity inflows, marking a record investment milestone in 2025. However, this surge has led to heightened competition among investors for premium assets, influencing market dynamics and raising strategic considerations for future investment and growth.
TCB Team·Jan 15, 2026 
Regulatory & PolicyThe burgeoning weight loss drug market has recently faced legal scrutiny as a compounding pharmacy alleges anticompetitive tactics by leading biopharmaceutical companies Eli Lilly and Novo Nordisk. This lawsuit brings further attention to the competitive dynamics and regulatory challenges in the obesity treatment sector.
TCB Team·Jan 15, 2026 
Regulatory & PolicyThe year 2025 marked a hopeful shift in the battle against drug overdose deaths in the United States, with federal data showing a decline across much of the year. This trend indicates that sustained public health and regulatory efforts may be yielding measurable benefits in a crisis that has impacted the nation for decades.
TCB Team·Jan 14, 2026 
Healthcare InvestmentDuring the JPM26 conference, Sanofi's leadership revealed their tactical move to buy shares in vaccine biotech company Dynavax amidst a backdrop of short-term market downturn caused by vaccine-related political controversies. This decision reflects Sanofi’s long-term confidence in vaccine innovation and market recovery.
TCB Team·Jan 14, 2026 
Biopharmaceutical IndustryAstraZeneca is positioning itself for substantial growth over the next decade. Key to its plan are advanced therapeutic modalities including antibody-drug conjugates (ADCs) and cell therapies, alongside a robust pipeline of products under FDA review targeting significant medical needs.
TCB Team·Jan 14, 2026 
Regulatory & PolicyIn a significant regulatory update, the U.S. Food and Drug Administration (FDA) has asked Novo Nordisk and Eli Lilly, leading makers of GLP-1 receptor agonists used for weight management, to remove suicide warnings from their product labels. This decision follows exhaustive analysis of clinical data demonstrating no causal link between these drugs and suicidal thoughts or actions.
TCB Team·Jan 14, 2026 
Medical TechnologyIn early 2026, Fullscript launched a partnership with ŌURA to incorporate biometric data from the ŌURA Ring into clinical workflows. This integration aims to enhance patient monitoring and support more informed healthcare decision-making using real-time wearable technology data.
TCB Team·Jan 14, 2026 
Biopharmaceutical IndustryAt the 2026 J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal revealed why the pharmaceutical giant is choosing to focus its resources away from GLP-1 agonists. This post explores the rationale behind Novartis’ approach and discusses the broader implications for the industry as GLP-1 drugs continue to proliferate.
TCB Team·Jan 14, 2026 
Medical TechnologyRecent developments in perfusion technologies have expanded the possibilities for organ transplantation, turning what was once a field constrained by scarcity into one characterized by growing opportunity and improved outcomes. By oxygenating and nourishing organs outside the body, these technologies allow for longer preservation and better clinical decision-making.
TCB Team·Jan 13, 2026 
Biopharmaceutical IndustryPfizer’s strategic move to fast-track its obesity treatment follows critical patent cliffs on key products. The accelerated development timeline reflects the company’s proactive efforts to sustain its market presence and address a growing public health concern.
TCB Team·Jan 13, 2026 